XYXiaoyun Yang

Xiaoyun Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaoyun Yang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Jiaying Zhong

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Lin Liu

    Oklahoma Center for Respiratory and Infectious Diseases Oklahoma State University Stillwater Oklahoma USA

    2 shared publications
  • Pixin Ran

    State Key Laboratory of Respiratory Diseases National Clinical Research Center for Respiratory Diseases Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China

    2 shared publications
  • Yumin Zhou

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Yurong Liang

    Oklahoma Center for Respiratory and Infectious Diseases Oklahoma State University Stillwater Oklahoma USA

    2 shared publications
  • Zhongfang Wang

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    2 shared publications

Latest Publications

  • Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy

    by Qiaoli Peng, Yik Chun Wong, Wing Yin Cheng, Yun He, Chengxi Xie, Yirong Shi, Ting Wang, Yanhua Du, Xiaoyun Yang, Zhongfang Wang, et al.

    Background: Therapeutic vaccines represent a potential strategy for HIV-1 control without antiretroviral therapy (ART). We report a first-in-human study on ICVAX™, a PD-1-enhanced HIV-1 therapeutic DNA vaccine. Methods: This NMPA-approved, randomized, double-blind, placebo-controlled, dose-escalation phase I trial (NCT06253533) was conducted at Shenzhen Third People's Hospital, China. Adults with HIV-1 aged 18–50 years on ART were sequentially allocated to 1, 2, or 4 mg dose groups of 15, each randomized 12:3 to ICVAX or placebo. Participants received intramuscular injections with electroporation at Weeks 0, 4, 8, 12, and 36. Primary safety, secondary immunological, and exploratory virological outcomes were recorded. Results: All 45 participants completed the trial, with 12 per ICVAX cohort and 9 in pooled Placebo. Treatment-related adverse events occurred in 100% of placebo and 83.3% of ICVAX recipients, all mild and transient, predominantly local reactions. A ≥2-fold increase of peak ELISpot T-cell responses over baseline was achieved by 75%, 75%, and 58.3% of low-dose, mid-dose, and high-dose recipients, versus 33.3% for Placebo. ICVAX recipients also showed low-frequency Gag-specific T cells expressing CD107a and/or effector cytokines. Conclusions: ICVAX was well-tolerated and elicited robust antigen-specific T-cell responses in ART-suppressed people with HIV-1. Its efficacy will be assessed in future studies.


  • Open Access

    Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection

    by Zhongfang Wang, Xiaoyun Yang, Jiaying Zhong, Yumin Zhou, Zhiqiang Tang, Haibo Zhou, Jun He, Xinyue Mei, Yonghong Tang, Bijia Lin, et al.

    T-cell immunity is important for recovery from COVID-19 and provides heightened immunity for re-infection. However, little is known about the SARS-CoV-2-specific T-cell immunity in virus-exposed individuals. Here we report virus-specific CD4+ and CD8+ T-cell memory in recovered COVID-19 patients and close contacts. We also demonstrate the size and quality of the memory T-cell pool of COVID-19 patients are larger and better than those of close contacts. However, the proliferation capacity, size and quality of T-cell responses in close contacts are readily distinguishable from healthy donors, suggesting close contacts are able to gain T-cell immunity against SARS-CoV-2 despite lacking a detectable infection. Additionally, asymptomatic and symptomatic COVID-19 patients contain similar levels of SARS-CoV-2-specific T-cell memory. Overall, this study demonstrates the versatility and potential of memory T cells from COVID-19 patients and close contacts, which may be important for host protection.


  • Open Access

    CLAG-M chemotherapy followed by umbilical cord blood stem cell transplantation for primary refractory acute myeloid leukaemia in a child: A case report

    by Jie Huang, Xiao-Yun Yang, Liu-Cheng Rong, Yao Xue, Jun Zhu, Yong-Jun Fang

    The prognosis of paediatric primary refractory/relapsed acute myeloid leukaemia (R/R AML) remains poor. Intensive therapy is typically used as salvage treatment for those with R/R AML. No data are currently available about the use of the CLAG-M protocol as salvage therapy in paediatric patients with R/R AML. An 8-year-old patient was diagnosed with acute myeloid leukaemia by bone marrow morphology and immunophenotype. The patient showed poor response to two cycles of induction therapy with 60% blast cells in the bone marrow after the second induction cycle. The patient achieved complete remission after being treated with the CLAG-M protocol as salvage therapy before undergoing umbilical cord blood stem cell transplantation. Morphological complete remission with haematological recovery has hitherto been maintained over 4 mo. Abnormal gene mutations detected at diagnosis were undetectable after haematopoietic stem cell transplantation. Here we present a paediatric patient with primary refractory acute myeloid leukaemia who was successfully treated with the CLAG-M protocol. Given the positive results of the presented patient, large-scale clinical studies are required to assess the role of the CLAG-M protocol in the salvage treatment of refractory or relapsed AML in childhood.


  • Open Access

    MicroRNA ‐206 inhibits influenza A virus replication by targeting tankyrase 2

    by Gayan Bamunuarachchi, Xiaoyun Yang, Chaoqun Huang, Yurong Liang, Yujie Guo, Lin Liu

    Due to the frequent mutations, influenza A virus (IAV) becomes resistant to anti‐viral drugs targeting influenza viral proteins. There are increasing interests in anti‐viral agents that target host cellular proteins required for virus replication. Tankyrase (TNKS) has poly (ADP‐ribose) polymerase activity and is a negative regulator of many host proteins. The objectives of this study are to study the role of TNKS2 in IAV infection, identify the microRNAs targeting TNKS2, and to understand the mechanisms involved. We found that TNKS2 expression was elevated in human lung epithelial cells and mouse lungs during IAV infection. Knock‐down of TNKS2 by RNA interference reduced viral replication. Using a computation approach and 3′‐untranslation regions (3′‐UTR) reporter assay, we identified miR‐206 as the microRNA that targeted TNKS2. Overexpression of miR‐206 reduced viral protein levels and virus production in cell culture. The effect of miR‐206 on IAV replication was strain‐independent. miR‐206 activated JNK/c‐Jun signalling, induced type I interferon expression and enhanced Stat signalling. Finally, the delivery of an adenovirus expressing miR‐206 into the lung of mice challenged with IAV increased type I interferon response, suppressed viral load in the lungs and increased survival. Our results indicate that miR‐206 has anti‐influenza activity by targeting TNKS2 and subsequently activating the anti‐viral state.


  • Open Access

    COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury

    by Zhongfang Wang, Xiaoyun Yang, Yumin Zhou, Jing Sun, Xiaoqing Liu, Jing Zhang, Xinyue Mei, Jiaying Zhong, Jincun Zhao, Pixin Ran


  • Open Access

    Saturation of influenza virus neutralization and antibody consumption can both lead to bistable growth kinetics

    by Shilian Xu, Ada W. C. Yan, Heidi Peck, Leah Gillespie, Ian G. Barr, Xiaoyun Yang, Stephen J. Turner, Celeste M Donato, Tonghua Zhang, Moshe Olshansky, et al.

    Influenza virus is a major human health threat. Neutralizing antibodies elicited through prior infection or vaccination play an irreplaceable role in protection from subsequent infection. The efficacy of antibody-dependent vaccines relies on both virus replication and neutralization, but their quantitative relationship was unknown. Here we use mathematical models to quantitatively investigate viral survivability determined by antibody concentration and inocula size. We performed focus reduction assays for 49 seasonal influenza A/H3N2 viruses circulating during 2017–2019 against influenza antisera raised in ferrets, and find that the antibody consumption rates of individual reactions were either small or large, and this was strongly positively correlated with virus saturation. Regardless of antibody consumption rate, virus-antibody interactions always lead to antibody-induced bistable viral kinetics. As a result, at a specific interval of antibody concentration, small viral inocula are eliminated but not large virus inocula, which is triggered by saturated virus neutralization or antibody consumption. Our finding highlights virus-antibody interaction with different antigenic properties, thereby explaining commonly observed influenza re-infection and enhancing vaccine efficiency.

  • Long non-coding RNA PSMB8-AS1 regulates influenza virus replication

    by Sunil More, Zhengyu Zhu, Kong Lin, Chaoqun Huang, Samuel Pushparaj, Yurong Liang, Roshini Sathiaseelan, Xiaoyun Yang, Lin Liu

    Long non-coding RNAs (lncRNAs) are a new arm of gene regulatory mechanism as discovered by sequencing techniques and follow-up functional studies. There are only few studies on lncRNAs as related to gene expression regulation and anti-viral activity during influenza virus infection. We sought to identify and characterize lncRNAs involved in influenza virus replication. Using RNA sequencing analysis, we found that 1,912 lncRNAs were significantly changed in human lung epithelial A549 cells infected with influenza A/Puerto Rico/8/34. Gene ontology analysis on neighboring genes of these lncRNAs revealed that the genes involved in type I interferon signaling and cellular response were highly enriched. Seven selected up-regulated lncRNAs (AC015849.2, RP-1-7H24.1, PSMB8-AS1, CTD-2639E6.9, PSOR1C3, AC007283.5 and RP11-670E13.5) were verified by real-time PCR. These lncRNAs were also induced by other two influenza H1N1 virus strains (A/WSN/1933 and A/Oklahoma/3052/09) and interferon β1. Repression of PSMB8 antisense RNA 1 (PSMB8-AS1) using CRISPR interference reduced viral mRNA and protein levels as well as the release of progeny influenza virus particles. Our study suggests that lncRNA PSMB8-AS1 could be a new host factor target for developing antiviral therapy against influenza virus infection.